KEYTRUDA
-
Merck Doubles Down on Domestic Manufacturing with $70 Billion Investment
Pharmaceutical giant Merck is boosting its U.S. investments to more than $70 billion, according to Reuters. The move underscores its…
-
Merck’s Oral Cholesterol Therapy Offers Easier Alternative to Injections
Merck, the pharmaceutical giant with multiple locations across Montco, is reporting success with a new oral cholesterol drug, according to…
-
WSJ: Merck Makes $10 Billion Move as Keytruda Patent Expiration Nears
Merck is making big pharma waves again with a $10 billion deal to acquire Verona Pharma, reports Colin Kellaher for…
-
Merck Expands Biomanufacturing with Staggering Investment in Wilmington
Merck, the Pharma giant with operations in Lansdale, announced on Tuesday that it will build a $1 billion “biologics center…
-
Mid-Stage Trials Show Some Promise for Merck’s Experimental Cancer Vaccine
An experimental cancer vaccine is being developed by Lansdale-centric Merck, with input from Moderna. The project’s mid-stage trials are showing…
-
Merck Skin Cancer mRNA Vaccine Shows Promising Results in Initial Trials
Merck, the pharmaceutical giant with sizable operations in West Point outside of Lansdale, and Moderna have announced promising results from…
-
Recent Activity in Oncology and Vaccine Lines of Business May Signal That Merck May Be Ready to Perk
Merck & Co. has raised its revenue outlook, based on a notable rise in sales for 3Q2022. Sabela Ojea reported…
-
Merck Acquiring Acceleron Pharma for Around $11.5B
Merck, the pharmaceutical giant with sizable operations in West Point, is acquiring Acceleron Pharma for around $11.5 billion, according to…
-
Merck’s Cancer Antibody Granted Another Approval by FDA
Merck, the pharmaceutical giant with sizable operations in West Point, has received another approval for its blockbuster cancer antibody Keytruda,…
-
Merck 1st-quarter revenues up 6 percent
Drugmaker Merck ‘s posted first quarter revenues of $10.04 billion this week, an increase of 6 percent driven by a…
-
Combination of Merck, Incyte Cancer Treatments Shows Promising Results
A new study combining the use of Merck’s Keytruda cancer treatment with Incyte’s immune-oncology drug Epacadostat, is showing promising results…
-
Merck Posts Excellent Quarterly Results But Issues Profit Warning from June’s Cyber Attack
Merck has reported excellent quarterly results with profits beating analysts’ estimates, but the company qualified the good news with a…
-
Merck & Co. a Finalist for Patient Impact Award
Amidst southeast Pennsylvania’s thriving life sciences industry, three companies stood out last year as the most prominent champions of the…
Founding Partners
Advertisement
Affiliate Partners
Community Partners
